The Elbs and Boyland- Sims peroxydisulfate oxidations

• E. J. Behrman

Beilstein J. Org. Chem. 2006, 2, No. 22, doi:10.1186/1860-5397-2-22

• E. J. Behrman Department of Biochemistry, The Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA 10.1186/1860-5397-2-22 Abstract This paper reviews the recent literature on the title reactions and updates a 1988 review. The Elbs and Boyland-Sims oxidations are shown in Scheme 1

• area is the use of salts of peroxydisulfate which are soluble in organic solvents by virtue of large organic cations in place of the commercially available ammonium, sodium, or potassium salts. This approach has not yet been reported for the Elbs or Boyland-Sims oxidations. Corresponding chemistry of

• Boyland (1905–2002) has appeared. [34][35][36] The Tables record the literature on the Elbs and Boyland-Sims oxidations from 1984 (the approximate literature cutoff for ref. 1) through mid-2006. There are also a few earlier references which were omitted from ref. 1. Key to the Tables: the Tables are

Towards practical biocatalytic Baeyer- Villiger reactions: applying a thermostable enzyme in the gram- scale synthesis of optically- active lactones in a two-liquid- phase system

• Frank Schulz,
• François Leca,
• Frank Hollmann and
• Manfred T. Reetz

Beilstein J. Org. Chem. 2005, 1, No. 10, doi:10.1186/1860-5397-1-10

• shows that the thermally stable phenylacetone monooxygenase (PAMO) and recently engineered mutants can be used as a practical catalysts for enantioselective Baeyer-Villiger oxidations of several ketones on a preparative scale under in vitro conditions. For this purpose several parameters such as buffer

• composition, the nature of the solvent system and the co-factor regeneration system were optimized. Overall a fairly versatile and efficient catalytic system for enantioselective laboratory scale BV-oxidations of ketones was developed, which can easily be applied even by those organic chemists who are not

• (NAD(P)H) for reductive O2-activation.[33][34][35] Another challenge is the cost-factor of the BVMOs themselves, since their use usually requires tedious purification steps. These complications are frequently addressed by performing biocatalytic BV-oxidations in vivo, i.e., using whole, metabolically